2015年欧洲甲状腺学会关于内因性亚临床甲状腺功能亢进症诊治指南解读  

Interpretation of the 2015 guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism by the European Thyroid Association

作　　者：肖方森[1,2] 李学军[2] 刘超[1] 

机构地区：[1]中国中医科学院江苏分院,南京中医药大学附属中西医结合医院内分泌代谢病院区,江苏南京210028 [2]厦门大学附属第一医院内分泌糖尿病科,福建厦门361003

出　　处：《中国实用内科杂志》2017年第1期24-27,共4页Chinese Journal of Practical Internal Medicine

摘　　要：亚临床甲状腺功能亢进症在临床中很常见,但对其危害及处理有很大的争议。欧洲甲状腺学会根据现有的临床证据,公布了内因性亚临床甲状腺功能亢进症诊治指南。指南强调,要确立持续性亚临床甲状腺功能亢进症的诊断,明确其病因,按照其进展为临床甲亢、发生不良心血管事件及骨质疏松风险进行危险分层,以指导临床处理。Endogenous subclinical hyperthyroidism （Endo SHyper） is a common form of thyroid diseases. Currently controversy exists in the management ofEndo SHyper. Based on the existing clinical evidence, the European Thyroid Association （ETA） published a guideline on diagnosis and treatment of Endo SHyper in 2015. The guidelines recommend that clinicians establish the diagnosis of persisted Endo SHyper, then clarify its etiology, and guide treatment by the risk stratification according to the development of overt hyperthyroidism, adverse cardiovascular events and osteoporosis.

关 键 词：亚临床甲状腺功能亢进 欧洲甲状腺学会 

分 类 号：R581.1[医药卫生—内分泌]